Abiopharma

Evolent reiterates Q2 and full year guidance for Adjusted EBITDA

Madrigal Receives Positive CHMP Opinion for Resmetirom(Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

Linde Publishes 2024 Sustainable Development Report

So-Young Announces Extension of Plan to Implement ADS Ratio Change

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

Q & M Dental Group (Singapore) Limited - Announcement

Netflix’s Movie Momentum in 2025: Big Names and Blockbusters

Cygnus raises $18.3m to accelerate resource growth and mining studies

Cygnus lève 18,3 M$ pour accélérer la croissance de ses ressources et ses études minières